Biosimilars developed by Samsung Bioepis will begin to be produced at the plants of its parent company Samsung BioLogics. An official at Samsung Bioepis said on May 3, “The company has recently signed a production contract with Samsung BioLogics,” adding, “The specific conditions of the contract can’t be disclosed.”
The industry insiders expect the biosimilar drugs are to be produced at the second plant of Samsung BioLogics with a capacity of 150,000 L that just started operating last month.
Industry watchers said the production contract between the two Samsung affiliates should be viewed as a natural step towards their expansion of global biopharmaceutical market share.
They also said that Samsung Group will enjoy the synergy effect as the two Samsung affiliates take up separate activities in R&D and production, which will enhance Samsung Group’s competiveness in the biopharmaceutical sector.
With the construction expected to be completed in 2018, Samsung BioLogics’ 3rd plant will be the world’s largest production site with a capacity of 360,000 L, which is larger than that of Lonza with 261,000 L in the U.S. and also that of Boehringer Ingelheim with 240,000 L in Germany.